

Erick Deconinck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5270625/erick-deconinck-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

263
papers

8,648
citations

52
h-index

86
g-index

283
ext. papers

9,847
ext. citations

4.5
avg, IF

4.94
L-index

#	Paper	IF	Citations
263	Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?. <i>Vaccine</i> , 2021 , 39, 7036-7043	4.1	0
262	Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. <i>Haematologica</i> , 2021 , 106, 3056-3066	6.6	8
261	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. <i>Blood Advances</i> , 2021 , 5, 1540-1551	7.8	10
260	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 193, 592-601	4.5	3
259	Oral therapy adherence and satisfaction in patients with multiple myeloma. <i>Annals of Hematology</i> , 2021 , 100, 1803-1813	3	0
258	Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, Aspergillus fumigatus qPCR, and Mucorales qPCR. <i>Journal De Mycologie Medicale</i> , 2021 , 31, 101117	3	
257	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021 , 60, 466-474	3.2	1
256	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021 , 56, 605-613	4.4	2
255	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 655-663	4.4	1
254	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1077-1085	4.4	1
253	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1305-1315	4.4	3
252	BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity. <i>EJHaem</i> , 2021 , 2, 128-133	0.9	
251	Platelet transfusions in haematologic malignancies in the last six months of life. <i>Vox Sanguinis</i> , 2021 , 116, 425-433	3.1	1
250	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021 , 35, 1291-1300	10.7	1
249	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 181-184	4.4	0
248	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 1597-1609	10.7	3
247	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021 , 35, 2332-2345	10.7	0

246	Lymphoblastic T Cells and Mature NK Cells With the Same TCR Rearrangement: A Common Origin?. <i>HemaSphere</i> , 2021 , 5, e608	0.3	
245	A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child. <i>Leukemia Research Reports</i> , 2021 , 16, 100262	0.6	
244	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1563-1572	4.4	0
243	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. <i>Frontiers in Oncology</i> , 2020 , 10, 599933	5.3	4
242	Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia. <i>JCO Oncology Practice</i> , 2020 , 16, 834-836	3.6	1
241	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1057-1065	7.1	4
240	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2647-2657	2.2	11
239	Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 491-500	3.1	6
238	Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 613-620	3.1	1
237	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1125	7.1	1
236	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 87	22.4	11
235	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , 2020 , 34, 3228-3241	3.7	13
234	CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2020 , 95, 892-899	7.1	4
233	Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. <i>Blood Advances</i> , 2020 , 4, 6327-6335	7.8	0
232	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2254-2260	4.4	4
231	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020 , 34, 1144-1153	10.7	4
230	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020 , 7, e50-e60	14.6	23
229	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5

228	Structural study of L-ascorbic acid 2-phosphate magnesium, a raw material in cell and tissue therapy. <i>Journal of Biological Inorganic Chemistry</i> , 2020 , 25, 875-885	3.7	3
227	Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation. <i>Platelets</i> , 2020 , 31, 536-540	3.6	8
226	Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman. <i>Case Reports in Hematology</i> , 2020 , 2020, 3686584	0.7	1
225	Clinical and biological features in -hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients. <i>Haematologica</i> , 2019 , 104, 1554-1564	6.6	42
224	EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). <i>Bone Marrow Transplantation</i> , 2019 , 54, 1391-1398	4.4	17
223	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1987-1994	4.4	15
222	Altered thymic CD4 T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis. <i>Current Research in Translational Medicine</i> , 2019 , 67, 135-143	3.7	2
221	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2060-2071	4.4	4
220	The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.. <i>Blood</i> , 2019 , 134, 494-494	2.2	8
219	Clinical Profile of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2019 , 134, 734-734	2.2	26
218	Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT. <i>Blood</i> , 2019 , 134, 4548-4548	2.2	
217	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019 , 134, 3338-3338	2.2	
216	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019 , 3, 4238-4251	7.8	27
215	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019 , 9, 88	7	13
214	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. <i>Cancer Research</i> , 2019 , 79, 663-675	10.1	38
213	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019 , 94, 231-239	7.1	7
212	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1657-1663	4.7	8
211	Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2018 , 67, 561-572	11.6	23

210	Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. <i>American Journal of Hematology</i> , 2018 , 93, 635-642	7.1	16
209	Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 468-475	13.4	53
208	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN analyzers in routine laboratory practice. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018 , 78, 159-164	2	5
207	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 751-757	4.7	28
206	Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study. <i>Transfusion</i> , 2018 , 58, 1377-1387	2.9	4
205	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018 , 131, 174-181	2.2	78
204	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018 , 93, 1142-1152	7.1	54
203	Development of a quantitative PCR detecting <i>Cunninghamella bertholletiae</i> to help in diagnosing this rare and aggressive mucormycosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1180-1183	4.4	14
202	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018 , 103, 1317-1328	6.6	54
201	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. <i>Haematologica</i> , 2018 , 103, 2033-2039	6.6	19
200	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018 , 9, 3379-3393	3.3	28
199	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018 , 132, 2162-2170	2.2	1
198	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC. <i>Blood</i> , 2018 , 132, 4663-4663	2.2	
197	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018 , 132, 4390-4390	2.2	
196	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , 2018 , 283, 371-379	10.8	15
195	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>American Journal of Hematology</i> , 2018 , 93, 416-423	7.1	12
194	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , 2017 , 54, 12-16	2.7	2
193	DNA damage response defect in Williams-Beuren syndrome. <i>International Journal of Molecular Medicine</i> , 2017 , 39, 622-628	4.4	3

192	Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>Annals of Oncology</i> , 2017 , 28, 2191-2198	10.3	6
191	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2017 , 178, 521-533	4.5	21
190	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017 , 92, 653-659	7.1	10
189	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. <i>American Journal of Hematology</i> , 2017 , 92, 344-350	7.1	9
188	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 372-380	4.4	35
187	Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2017 , 102, 1861-1868	6.6	30
186	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2102	59.2	11
185	Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant. <i>Mycopathologia</i> , 2017 , 182, 761-765	2.9	7
184	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017 , 1, 477-485	7.8	57
183	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 2099-2110	27.4	75
182	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). <i>Blood</i> , 2016 , 128, 782-782	2.2	17
181	Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia. <i>Blood</i> , 2016 , 128, 2272-2272	2.2	
180	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016 , 128, 2272-2272	2.2	
179	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016 , 128, 2417-2417	2.2	
178	Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016 , 128, 2899-2899	2.2	
177	Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM. <i>Blood</i> , 2016 , 128, 3569-3569	2.2	
176	Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. <i>Blood</i> , 2016 , 128, 3476-3476	2.2	
175	Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. <i>Blood</i> , 2016 , 128, 895-895	2.2	

174	Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016 , 128, 2280-2280	2.2	
173	Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts. <i>Gene Therapy</i> , 2016 , 23, 664-72	4	6
172	Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1140-2	4.4	1
171	Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016 , 101, 1120-7	6.6	14
170	Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate. <i>Acta Dermato-Venereologica</i> , 2015 , 95, 495-6	2.2	4
169	Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Soci� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1452-9	4.7	8
168	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Soci� Fran�aise de Greffe de Moelle et	4.7	8
167	Combining Aspergillus mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients. <i>Medical Mycology</i> , 2015 , 53, 760-4	3.9	8
166	Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1586-4	4.4	7
165	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>European Journal of Haematology</i> , 2015 , 94, 449-55	3.8	7
164	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2015 , 121, 1048-55	6.4	56
163	A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. <i>American Journal of Hematology</i> , 2015 , 90, 811-8	7.1	51
162	In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. <i>Haematologica</i> , 2015 , 100, 223-30	6.6	49
161	Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients involvement in specific therapies decision-making. <i>BMC Palliative Care</i> , 2015 , 14, 61	3	7
160	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. <i>Experimental Hematology and Oncology</i> , 2015 , 5, 7	7.8	9
159	Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). <i>European Journal of Haematology</i> , 2015 , 94, 265-9	3.8	28
158	Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study. <i>Blood</i> , 2015 , 126, 1922-1922	2.2	0
157	Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015 , 126, 2111-2111	2.2	1

156	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. <i>Blood</i> , 2015 , 126, 3214-3214	2.2	1
155	How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network. <i>Blood</i> , 2015 , 126, 456-456	2.2	3
154	Identification of (antioxidative) plants in herbal pharmaceutical preparations and dietary supplements. <i>Methods in Molecular Biology</i> , 2015 , 1208, 181-99	1.4	8
153	Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study. <i>Blood</i> , 2015 , 126, 3203-3203	2.2	
152	Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC. <i>Blood</i> , 2015 , 126, 5444-5444	2.2	
151	Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French	2.2	
150	Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). <i>Blood</i> , 2015 , 126, 4367-4367	2.2	
149	Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA. <i>Blood</i> , 2015 , 126, 1946-1946	2.2	
148	Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice. <i>Medical Mycology</i> , 2014 , 52, 728-35	3.9	6
147	Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1841-6	4.7	40
146	Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: lack of lymphocyte recovery as a major contributing factor. <i>Pathologie Et Biologie</i> , 2014 , 62, 156-61		16
145	Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. <i>Haematologica</i> , 2014 , 99, 535-40	6.6	34
144	Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1095-104	11.6	74
143	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. <i>Leukemia</i> , 2014 , 28, 2367-75	10.7	239
142	Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin lymphoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 168-74	2.2	32
141	Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. <i>Leukemia</i> , 2014 , 28, 2422-4	10.7	37
140	Azole-resistant <i>Aspergillus fumigatus</i> isolate with the TR34/L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 1724-6	9.7	27
139	Evaluation of invasive aspergillosis risk of immunocompromised patients alternatively hospitalized in hematology intensive care unit and at home. <i>Indoor Air</i> , 2014 , 24, 652-61	5.4	21

138	A 10-year survey of fungal aerocontamination in hospital corridors: a reliable sentinel to predict fungal exposure risk?. <i>Journal of Hospital Infection</i> , 2014 , 87, 34-40	6.9	18
137	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. <i>Blood</i> , 2014 , 124, 187-187	2.2	2
136	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. <i>Blood</i> , 2014 , 124, 545-545	2.2	1
135	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014 , 124, 681-681	2.2	
134	Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. <i>Blood</i> , 2014 , 124, 2581-2581	2.2	
133	Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 3945-3945	2.2	
132	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 1230-1230	2.2	0
131	E-santé organisation des soins : structuration de la thérapeutique anti-cancéreuse en Franche-Comté <i>European Research in Telemedicine</i> , 2013 , 2, 101-107		1
130	A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. <i>Leukemia Research Reports</i> , 2013 , 2, 29-31	0.6	13
129	Chromatography in the detection and characterization of illegal pharmaceutical preparations. <i>Journal of Chromatographic Science</i> , 2013 , 51, 791-806	1.4	54
128	Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1238-43	4.7	86
127	Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Bone Marrow Transplantation</i> , 2013 , 48, 684-90	4.4	2
126	Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. <i>Experimental Hematology</i> , 2013 , 41, 924-33	3.1	24
125	Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells. <i>Molecular Immunology</i> , 2013 , 56, 123-8	4.3	4
124	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>European Journal of Haematology</i> , 2013 , 90, 355-64	3.8	52
123	Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. <i>American Journal of Hematology</i> , 2013 , 88, 556-9	7.1	25
122	Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. <i>Transplantation</i> , 2013 , 95, 1284-91	1.8	52
121	Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT. <i>Blood</i> , 2013 , 122, 2156-2156	2.2	3

120	Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial. <i>Blood</i> , 2013 , 122, 2691-2691	2.2	2
119	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL: Second Interim Analysis Of A Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , 2013 , 122, 495-495	2.2	
118	Antithymocyte Globulin and Role Of Stem Cell Source On Outcome In Myeloablative Conditioning Of Allogeneic Hematopoietic Stem Cell Transplantation With Identical Sibling and Matched Unrelated Donors - A Retrospective Study Of French Society Of Bone Marrow Graft Transplantation and Cellular Therapy - <i>Blood</i> , 2013 , 122, 3382-3382	2.2	
117	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients: A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013 , 122, 921-921	2.2	
116	Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2012 , 88, 269-72	3.8	6
115	CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012 , 81, 17-24	4.6	25
114	Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélobdysplasies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4533-40	2.2	160
113	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012 , 23, 2380-2385	10.3	40
112	Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 250-6	4.7	4
111	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 788-93	4.7	77
110	Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 27	22.4	29
109	Intracytoplasmic detection of TCL1--but not ILT7--by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012 , 81, 718-24	4.6	16
108	Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution. <i>Investigational New Drugs</i> , 2012 , 30, 1697-702	4.3	2
107	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012 , 23, 2187-2195	10.3	23
106	Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3848-53	2.2	92
105	Two Years Follow-up Results of Graspall/Graall-SA2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). <i>Blood</i> , 2012 , 120, 1473-1473	2.2	1
104	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , 2012 , 120, 890-890	2.2	1
103	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , 2012 , 120, 906-906 ^{2.2}	2.2	3

102	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2012 , 120, 1975-1975	2.2	
101	Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe franc aise De Greffe De Moelle Et De Therapie Cellulaire. <i>Blood</i> , 2012 , 120, 2008-2008	2.2	
100	Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. <i>Environment International</i> , 2011 , 37, 449-53	12.9	54
99	Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 935-40	4.7	6
98	Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation. <i>Blood</i> , 2011 , 118, 476-8	2.2	4
97	Retrospective assessment of BD-(1,3)-glucan for presumptive diagnosis of fungal infections. <i>Apmis</i> , 2011 , 119, 280-6	3.4	15
96	Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. <i>Bone Marrow Transplantation</i> , 2011 , 46, 858-62	4.4	28
95	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011 , 96, 1128-35	6.6	84
94	Ribosomal and mitochondrial DNA target for real-time PCR diagnosis of invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 1058-63	9.7	26
93	Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome. <i>Bone Marrow Transplantation</i> , 2011 , 46, 622-4	4.4	6
92	Complete Remission After First-Line Radio Plus Chemotherapy Is Enough to Improve Survival in Extra Nodal NK/T Cell lymphoma. <i>Blood</i> , 2011 , 118, 2679-2679	2.2	1
91	The IL-3R α Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. <i>Blood</i> , 2011 , 118, 2588-2588	2.2	
90	L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph- ALL): First Results of the GRASPALL/GRAALL-SA2-2008 Study. <i>Blood</i> , 2011 , 118, 2579-2579	2.2	
89	Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group. <i>Blood</i> , 2011 , 118, 3035-3035	2.2	
88	Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. <i>British Journal of Haematology</i> , 2010 , 151, 159-66	4.5	110
87	Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. <i>Bone Marrow Transplantation</i> , 2010 , 45, 177-80	4.4	5
86	Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4926-34	2.2	64
85	False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease. <i>Medical Mycology</i> , 2010 , 48, 661-4	3.9	21

84	Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. <i>Pharmacoeconomics</i> , 2010 , 28, 35-46	4.4	35
83	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , 2010 , 115, 2420-9	2.2	52
82	G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. <i>Blood</i> , 2010 , 115, 910-1	2.2	13
81	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010 , 95, 1350-7	6.6	34
80	Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. <i>International Journal of Medical Informatics</i> , 2010 , 79, 699-706	5.3	43
79	Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytopheresis in normal peripheral blood stem cell donors. <i>Transfusion</i> , 2010 , 50, 2676-85 ⁹	2.9	9
78	Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group. <i>Blood</i> , 2010 , 116, 13-13	2.2	3
77	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial. <i>Blood</i> , 2010 , 116, 1344-1344	2.2	2
76	Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant Disorders. A Eurocord-EBMT Analysis. <i>Blood</i> , 2010 , 116, 223-223	2.2	3
75	No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial. <i>Blood</i> , 2010 , 116, 685-685	2.2	7
74	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , 2010 , 116, 910-910	2.2	6
73	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010 , 116, 2171-2171	2.2	
72	Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2010 , 116, 2359-2359	2.2	
71	Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2668-76	2.2	78
70	Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report. <i>Liver Transplantation</i> , 2009 , 15, 682-5	4.5	19
69	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , 2009 , 145, 624-36	4.5	128
68	Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1134-9	4.7	13
67	Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 667-75	6.2	26

66	Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. <i>Pharmacoeconomics</i> , 2009 , 27, 55-68	4.4	8
65	Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2009 , 94, 542-9	6.6	83
64	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009 , 113, 995-1001	2.2	116
63	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Experimental Hematology</i> , 2008 , 36, 535-44	3.1	47
62	Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4940-3	2.2	74
61	Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?. <i>Human Gene Therapy</i> , 2008 , 19, 937-50	4.8	23
60	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. <i>Blood</i> , 2008 , 112, 139-139	2.2	2
59	Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. <i>Transfusion</i> , 2007 , 47, 1268-75	2.9	55
58	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , 2007 , 92, 627-34	6.6	78
57	Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. <i>Blood</i> , 2007 , 110, 3842-52	2.2	19
56	Refractory Hemorrhagic Cystitis after Hematopoietic Stem Cell Transplantation: Clinical Benefit of Factor XIII. <i>Blood</i> , 2007 , 110, 4935-4935	2.2	
55	Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5703-10	2.2	142
54	Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) Resolves Gastrointestinal Disorders in a Patient with Severe Idiopathic Aplastic Anaemia. <i>Drugs</i> , 2006 , 66, 33-35	12.1	
53	Quantification de Stachybotrys chartarum par PCR en temps réel dans l'environnement domestique, hospitalier, et agricole. <i>Journal De Mycologie Medicale</i> , 2006 , 16, 183-188	3	4
52	Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 448-54	4.7	4
51	Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Drug Investigation</i> , 2005 , 25, 719-29	3.2	5
50	Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. <i>Blood</i> , 2005 , 105, 1256-64	2.2	65
49	The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. <i>Blood</i> , 2005 , 105, 862-4	2.2	67

48	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , 2005 , 105, 3817-23	2.2	156
47	c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. <i>British Journal of Haematology</i> , 2005 , 128, 767-73	4.5	66
46	Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005 , 35, 859-68	4.4	24
45	Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. <i>Annals of Oncology</i> , 2005 , 16, 466-72	10.3	17
44	Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 5097-101	9.7	64
43	Transgene Deletions in Long-Term Circulating Donor Gene-Modified T Lymphocytes Infused at Time of Hematopoietic Transplantation.. <i>Blood</i> , 2005 , 106, 461-461	2.2	1
42	Cidofovir: A Treatment for BK Virus Cystitis after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2005 , 106, 5354-5354	2.2	
41	Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1260-7	2.2	35
40	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2004 , 33, 531-4	4.4	45
39	Renal toxicity after bone marrow transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 661-2	4	2
38	Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. <i>New England Journal of Medicine</i> , 2004 , 350, 1287-95	59.2	287
37	A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P-glycoprotein-negative high-risk myelodysplastic syndromes. <i>The Hematology Journal</i> , 2004 , 5, 209-15		3
36	Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. <i>Blood</i> , 2003 , 102, 4261-9	2.2	377
35	A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. <i>Bone Marrow Transplantation</i> , 2003 , 31, 909-18	4.4	52
34	Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. <i>Leukemia</i> , 2003 , 17, 339-42	10.7	60
33	Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2003 , 14, 277-81	10.3	100
32	A single intravenous infusion of apoptotic cells, an alternative cell-based therapy approach facilitating hematopoietic cell engraftment, did not induce autoimmunity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003 , 12, 451-9		7
31	Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. <i>Journal of Neurology</i> , 2002 , 249, 1088-97	5.5	181

30	Polyvisceral arteritis in chronic graft-versus-host disease: antiphospholipid-negative thrombotic syndrome mimicking polyarteritis nodosa. <i>Bone Marrow Transplantation</i> , 2002 , 29, 873-4	4.4	1
29	Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. <i>Leukemia</i> , 2002 , 16, 726-35	10.7	35
28	Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. <i>Transplantation</i> , 2002 , 74, 1190-2	1.8	22
27	Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. <i>Blood</i> , 2001 , 97, 63-72	2.2	245
26	Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. <i>Blood</i> , 2001 , 98, 2640-4	2.2	92
25	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001 , 97, 101-6	2.2	457
24	Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. <i>Journal of Clinical Oncology</i> , 2000 , 18, 780-7	2.2	69
23	Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. <i>British Journal of Haematology</i> , 2000 , 109, 736-42	4.5	48
22	Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 25, 1111-4	4.4	52
21	Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. <i>Journal of Clinical Oncology</i> , 2000 , 18, 963-71	2.2	180
20	Toxoplasmosis after hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , 2000 , 31, 1188-95	4.5	171
19	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000 , 111, 801-6	4.5	104
18	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 1192-1200	2.2	606
17	Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation. <i>Hematology and Cell Therapy</i> , 1999 , 41, 31-7		3
16	Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998 , 21, 943-6	4.4	13
15	Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. <i>Leukemia</i> , 1998 , 12, 213-9	10.7	27
14	High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1998 , 9 Suppl 1, S5-8	10.3	4
13	Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2060-4	2.2	82

12	Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patients. <i>Annals of Oncology</i> , 1997 , 8, S49-S52	10.3	18
11	Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Étude des Lymphomes de l'Adulte. <i>Leukemia and Lymphoma</i> , 1997 , 25, 289-300	1.9	86
10	Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. <i>Human Gene Therapy</i> , 1997 , 8, 615-24	4.8	74
9	Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Étude des Lymphomes de l'Adulte study on 453 patients older than 69 years. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2945-53	2.2	181
8	Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). <i>Bone Marrow Transplantation</i> , 1997 , 20, 731-5	4.4	21
7	Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 1997 , 20, 975-82	4.4	22
6	A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. <i>Blood</i> , 1996 , 88, 2480-2487	2.2	123
5	High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1996 , 51, 334	7.1	5
4	Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. <i>Transplantation</i> , 1995 , 59, 151-5	1.8	36
3	Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. <i>Leukemia and Lymphoma</i> , 1993 , 11, 359-68	1.9	18
2	Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? [letter; comment]. <i>Blood</i> , 1992 , 80, 2149-2150	2.2	16
1	Aplasie post-chimiothérapie et autogreffe de moelle osseuse: apport des facteurs de croissance hématopoïétiques. <i>Revue De Médecine Interne</i> , 1991 , 12, S271-S273	0.1	